Главная > Blogs > Vaxil Presents My Inventions As Vaxil’s Own
Vaxil Presents My Inventions As Vaxil’s Own20-01-2014, 22:25. Разместил: admin |
|
Vaxil Presents My Inventions As Vaxil’s Own Alexander Cherkasky alexcherkasky@googlemail.com My published German patent application DE19951694 (from the year 1999 (Filing date: October 27, 1999)), which damages and claims priority worldwide, discloses also in the claims 4 and 9 fusion proteins comprising random proteins of interest and membrane penetration domains (MPD) as well as fusion proteins comprising random proteins of interest and signal peptides, i.e. signal peptide domains. Thus these fusion proteins can migrate in extracellular and intracellular space (claim 4). This my invention of fusion proteins comprising any protein and signal peptide domain, disclosed in DE19951694, was descibed and plagiaristically used by the Israeli company Vaxil (by Lior Carmon) in its US20120177677 (”Antigen Specific Multi-Epitope-Based Anti-infective Vaccines”), WO2011007359 and EP2453914 (from the years 2009 and 2010) and ”Antigen Specific Multi Epitope Vaccines” (US20100074925 (claims 39, 57, 58), EP2089423, WO2008035350, CA2665816 and AU2007298494). In these publications Vaxil described ”peptide vaccines including the signal peptide domain” (Abstract of US20120177677 as well as claim 29 (”a vaccine comprising a peptide or a recombinant polypeptide(!) consisting of at least one signal peptide domain(!) of at least one target protein(!) of a intracellular(!) pathogen”) and claim 36 (”restriction enzyme sites” were disclosed in my DE19925052 A1, claims 9, 12 and 20 (for therapeutic use)) and claim 42 of Vaxil’s US20120177677). But as mentioned above these descriptions of Vaxil (Vaxil BioTherapeutics Ltd. (TASE:VAXL)) are not new and not inventive because of my DE19951694. Investors of Vaxil must know this information, because this key intellectual property of Vaxil can be lost (for example, patents will not be granted or if granted by errors of examiners, the patents can be rejected after reexamination with the United States Patent and Trademark Office (USPTO)), and thus products/product canditates of Vaxil can not be protected from competitors. Вернуться назад |